AUROPHARMA Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Aurobindo Pharma delivered its highest-ever quarterly revenue of ₹10,263 crores (+24% YoY) with operating EBITDA of ₹2,156 crores (+28% YoY) at 21% margin despite input cost and freight headwinds. Growth was broad-based across US (+25% YoY, $477M), Europe (+18% cc, €288M), API (+21% YoY), and Growth Markets (+16% YoY). Gross margin expanded 150 bps YoY to 61.2%. The company completed the Lannett acquisition, acquired A1 Biochem for CRDMO, launched ADQUEY (first NDA) and generic Advair, and received VAI classification for Raleigh. Net cash position of $189M with strong quarterly cash flow of $146M. FY27 guidance reiterated: double-digit revenue growth, EBITDA margins >21%, absolute EBITDA >₹8,000 crores. FY28 expected to be 'far better than FY27' with 22%+ EBITDA margins. Key monitorables: Lannett integration and utilization, China facility breakeven, respiratory pipeline progress, biosimilar strategy execution, and Pen-G PLI benefits.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted record revenue, strong growth across all segments (US +25%, Europe +18% cc, API +21%), margin expansion, and clear strategic priorities with reiterated FY27 guidance and FY28 margin outlook of 22%+.
- Q&A Session: Good — Management provided detailed, direct responses on margin drivers, Lannett performance, respiratory pipeline, biosimilar strategy, and China facility breakeven. Some questions on Lannett contribution and specific product sizes were deflected, but overall tone was confident and informative.
Revenue Growth Drivers
- Lannett acquisition contributing to US revenue and portfolio expansion
- Europe business strong growth ahead of industry with new launches and market share gains
- US business growth from complex products, gAdvair launch, and Pomalidomide shared exclusivity
Growth vs Margin Focus
Management emphasizes balanced approach with focus on sustainable growth, product mix improvement, manufacturing efficiencies, and margin expansion. FY27 guidance includes double-digit revenue growth AND EBITDA margins north of 21% with absolute EBITDA >₹8,000 crores. FY28 targets 22%+ EBITDA margin
About Aurobindo Pharma Limited
Aurobindo Pharma Limited (AUROPHARMA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.